EUCTR2012-005037-37-ES进行中（未招募）1 期
A Phase I/II Trial of Temsirolimus Plus Neratinib for Patients with Metastatic HER2-Amplified or Triple-Negative Breast Cancer
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 65
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Phase 1 HER2-Amplified (HER2-Positive) Cohort - Closed to accrual
- •Phase 1 Triple-Negative Cohort - Closed to accrual
- •Phase 2 Triple-Negative Cohort - Closed to accrual
- •Phase 2 HER2-Positive Cohort with dose escalation
- •- HER2 overexpression and/or amplification as determined by IHC (3+) or FISH (>=2.0).
- •- Previously received trastuzumab as part of a regimen in the adjuvant or metastatic setting with evidence of progression. Washout period for trastuzumab of 14 days.
- •- May have previously received lapatinib as part of a regimen in the adjuvant or metastatic setting with evidence of progression of disease. Washout period for lapatinib of 14 days.
- •- Radiographic progression of disease while on treatment with trastuzumab as defined by RECIST 1.1 criteria.
- •- Prior therapy inclusion:
- •o No restriction on prior chemotherapy regimens for advanced stage disease. No restriction for prior hormonal therapy. No concurrent use of endocrine therapy is permitted.
- •Inclusion Criteria for ALL patients
- •- Patients with a diagnosis of invasive adenocarcinoma of the breast confirmed by histology or cytology.
- •- Metastatic disease that is or has been pathologically documented.
- •- At least one measurable metastatic lesion according to RECIST 1.1 criteria. Ascites, pleural effusions, and bone metastases are not considered measurable. Minimum indicator lesion size ?10 mm by helical computerized tomography (CT) or ?20 mm by conventional techniques.
- •o Pathological nodes must be ?15 mm by the short axis to be considered measurable.
- •- Age ?18, as no dosing or adverse event data are currently available on the use of neratinib or temsirolimus in patients <18 years of age.
- •- Patients must be willing to discontinue sex hormonal therapy, e.g., birth control pills, hormonal replacement therapy, prior to enrollment. Women of childbearing potential must consent to use effective contraception while on treatment and for 28 days thereafter. Men must consent to use a barrier method of contraception while on treatment and for 3 months thereafter.
- •- Negative serum human chorionic gonadotropin (HCG) pregnancy test for premenopausal women of reproductive capacity and for women less than 12 months after menopause.
- •- Asymptomatic, central nervous system metastases are permitted if patients remain clinically stable after discontinuation of steroids and anticonvulsants for 3 months.
- •- Eastern Cooperative Oncology Group (ECOG) performance status score of ?2.
- •- Patients must have normal organ and marrow function: AST/ALT ?2.5x institutional upper limit of normal except for patients with liver metastases. For patients with liver metastases, AST/ALT/alkaline phosphatase ?5.0 x institutional upper limit of normal. Total bilirubin within institutional limits except for patients with liver metastases. For patients with liver metastases, total bilirubin ?1.5x institutional upper limit of normal. Creatinine clearance within normal limits or ?60 mL/min, PT and PTT ?1.5x institutional upper limit of normal except for patients on Coumadin or low molecular weight heparin, leukocytes ?3,000/µL, absolute neutrophil count ?1,000/µL, and platelets ?75,000/µL.
- •- Able to swallow and retain oral medication.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 35
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •- Patients receiving any concurrent anticancer therapy or investigational agents with the intention of treating breast cancer.
- •-Previous treatment with any strong inhibitor and/or inducer of CYP3A4 enzyme or sensitive P glycoprotein (P gp) substrates ?30 days prior to initiation of investigational products.
- •- History of allergic reactions attributed to compounds of similar chemical or biologic composition to neratinib or temsirolimus.
- •- Women who are pregnant or breast feeding.
- •- Life expectancy <3 months.
- •- Completion of previous chemotherapy regimen <3 weeks prior to the start of study treatment. Prior hormonal therapy must be discontinued prior to treatment start. Biologic therapy with bevacizumab for the treatment of metastatic disease must be discontinued ?3 weeks from the start of protocol treatment.
- •- Concurrent radiotherapy is not permitted for disease progression on treatment on protocol, but might be allowed for pre-existing non-target lesions with approval from the Sponsor.
- •- Concurrent medical conditions which may increase the risk of toxicity, including ongoing or active infection, history of significant bleeding disorder unrelated to cancer (congenital bleeding disorders, acquired bleeding disorders within one year), human immunodeficiency virus (HIV)-positive or active hepatitis.
- •- History of clinically significant or uncontrolled cardiac disease, including congestive heart failure, angina, myocardial infarction, arrhythmia, and left ventricular ejection fraction less than 50% measured by a multigated acquisition imaging (MUGA scan) of the heart or an echocardiogram (ECHO).
- •- QTc interval >0.47 seconds.
- •- Patients with GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, or uncontrolled inflammatory GI disease.
- •- History of an invasive second primary malignancy diagnosed within the previous 3 years, except for stage I endometrial or cervical carcinoma or prostate carcinoma treated surgically, and non-melanoma skin cancer.
- •- History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance of oral drug intake.
- •- Unwillingness to give written informed consent, unwillingness to participate, or inability to comply with the protocol for the duration of the study. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures are necessary to participation in this clinical trial.
研究者
相似试验
进行中（未招募）
1 期
A clinical study of Temsirolimus and Neratinib in patients with breast cancer who have a specific genetic make up.EUCTR2012-005037-37-DKPuma Biotechnology, Inc.181
进行中（未招募）
1 期
A clinical study of Temsirolimus and Neratinib in patients with breast cancer who have a specific genetic make up.EUCTR2012-005037-37-GBPuma Biotechnology, Inc.99
进行中（未招募）
不适用
CESAR Study in Prostrate Cancer with Temsirolimus added to standard Docetaxel therapy (CEPTAS)castration resistant prostate cancer (CRPC)MedDRA version: 14.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-018370-21-DECESAR Central European Society for Anticancer Drug Research EWIV122
进行中（未招募）
1 期
/AAdvanced hormone - and chemotherapy - resistant prostate cancerEUCTR2011-002087-24-GRHellenic Oncology Research Group (HORG)
进行中（未招募）
不适用
A phase Ib study of combination of temsirolimus (Torisel®) and pegylated liposomal doxorubicin (PLD, Doxil®/ Caelyx®) in advanced or recurrent breast, endometrial and ovarian cancerEUCTR2009-010290-21-NLniversity Medical Centre Nijmegen St Radboud